Zacks Investment Research cut shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a buy rating to a hold rating in a research note published on Tuesday, January 9th.
According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
Several other equities research analysts have also recently issued reports on the stock. Canaccord Genuity reaffirmed a buy rating and set a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Cowen reaffirmed an outperform rating and set a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. Cantor Fitzgerald initiated coverage on shares of Aldeyra Therapeutics in a research note on Tuesday, October 24th. They set an overweight rating and a $22.00 price target on the stock. Finally, ValuEngine lowered shares of Aldeyra Therapeutics from a hold rating to a sell rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $17.42.
Shares of Aldeyra Therapeutics (ALDX) remained flat at $$6.65 during trading on Tuesday. The company’s stock had a trading volume of 59,400 shares, compared to its average volume of 99,300. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35. Aldeyra Therapeutics has a 12-month low of $3.80 and a 12-month high of $11.90. The company has a market cap of $132.87, a PE ratio of -4.72 and a beta of 0.53.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.09. sell-side analysts predict that Aldeyra Therapeutics will post -1.36 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu KCG Holdings LLC purchased a new stake in shares of Aldeyra Therapeutics during the second quarter valued at approximately $104,000. Bank of New York Mellon Corp purchased a new stake in shares of Aldeyra Therapeutics during the third quarter valued at approximately $134,000. Vanguard Group Inc. grew its position in shares of Aldeyra Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after buying an additional 9,407 shares in the last quarter. 683 Capital Management LLC grew its position in shares of Aldeyra Therapeutics by 59.1% during the third quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock worth $6,016,000 after buying an additional 310,421 shares in the last quarter. Finally, Sphera Funds Management LTD. grew its position in shares of Aldeyra Therapeutics by 19.2% during the third quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock worth $7,518,000 after buying an additional 168,200 shares in the last quarter. Hedge funds and other institutional investors own 47.89% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/19/zacks-investment-research-lowers-aldeyra-therapeutics-aldx-to-hold.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.